



Addex Pharmaceuticals

Full Year 2008
Financial Results
February 24, 2009

Disclaimer

These materials do not constitute or form part, or all, of any offer or invitation to sell or issue, neither in the United States of America nor elsewhere, or any solicitation of any offer to purchase or subscribe for, any securities, nor shall part, or all, of these materials or their distribution form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities.

These materials contain forward-looking statements based on the currently held beliefs and assumptions of the management of Addex Pharmaceuticals Ltd, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of Addex Pharmaceuticals Ltd, or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this document are cautioned not to place undue reliance on these forward-looking statements. Addex Pharmaceuticals Ltd disclaims any obligation to update these forward-looking statements to reflect future events or developments.

These materials are strictly confidential and must not be disclosed or distributed to third parties.

The Company



- Addex (SIX:ADXN) is located in Geneva, Switzerland
- Goal: allosteric modulators for human health
- Focus: CNS, Inflammation, Metabolic Disorders
- Pipeline: 2 Phase II programs, 1 Phase I program & 12 preclinical programs
- 135 people / founded in 2002
- Validating deals with J&J and Merck & Co., Inc.

2008 Achievements

- \$702 million deal with Merck & Co., Inc., signed
- ADX10059 modified release formulation (MR) development completed
- ADX10059 MR shown to be better tolerated and active in Phase I testing
- Three Phase IIb trials of ADX10059 MR initiated
 - Two GERD studies (monotherapy & PPI add-on)
 - On migraine prevention study
- 2008 stock performance: -3.7%

Financial Results

Financial Highlights



- Cash and cash equivalents CHF119.5 m at 31 Dec 2008
- Revenues increased to CHF26.9 m from CHF0.6 m
- Operating loss reduced to CHF24.9 m from CHF37.6 m
- Net cash burn below guidance of CHF25-30 m at CHF20.6 m
- 2009 cash burn guidance: CHF40-45 m

Financial Results 2008

Consolidated Balance Sheets



| In CHF thousands | Dec 31, 2008 | Dec 31, 2007 | Variance | In % |
|---|----------------|----------------|----------------|-------------|
| Cash and cash equivalents | 119'471 | 140'045 | -20'574 | -15% |
| Other current assets | 3'126 | 3'638 | -512 | -14% |
| Property, plant and equipment | 8'994 | 4'950 | +4'044 | +82% |
| Other non-current assets | 737 | 742 | -5 | -1% |
| Total assets | 132'328 | 149'375 | -17'047 | -11% |
| Payables and accruals | 11'469 | 5'946 | +5'523 | +93% |
| Deferred income | 1'868 | 3'321 | -1'453 | -44% |
| Shareholders' equity | 118'991 | 140'108 | -21'117 | -15% |
| Total liabilities and shareholders' equity | 132'328 | 149'375 | -17'047 | -11% |


Financial Results 2008

Consolidated Income Statements




| In CHF thousands | FY 2008 | FY 2007 | Variance | In % |
|---|-----------------|-----------------|----------------|-------------|
| Income | 26'874 | 643 | +26'231 | +4'079% |
| Research and development | (44'192) | (27'497) | +16'695 | +61% |
| General and administration | (7'554) | (10'768) | -3'214 | -30% |
| - <i>G&A excluding IPO related costs</i> | <i>(7'554)</i> | <i>(5'098)</i> | <i>+2'456</i> | <i>+48%</i> |
| Operating loss | (24'872) | (37'622) | +12'750 | -34% |
| - <i>Operating loss excluding IPO related costs</i> | <i>(24'872)</i> | <i>(31'952)</i> | <i>+7'080</i> | <i>-22%</i> |
| Finance income, net | 2'805 | 2'536 | +269 | +11% |
| Loss for the period | (22'066) | (35'086) | +13'020 | -37% |
| Basic and diluted loss per share/CHF | (3.85) | (6.99) | -3.14 | -45% |

Head Count Development



71% increase in headcount in 2008

Cash Development Full Year 2008



Cash flows in CHF' millions

Merck Deals: Accounting Treatment



- mGluR5 PAM deal entered into on January 2, 2008
 - Addex has no continuing involvement in the development
 - Upfront of \$22m (CHF24.8m) recognized in January 2008
- mGluR4 PAM first milestone achieved
 - Total milestone of CHF271K (\$250K) recognized over 21 mths
 - Recognition starts on March 1, 2008
 - CHF128'917 recognized as at Dec 31, 2008
- mGluR4 PAM technology access fee of CHF288K (\$250K) received.
 - Recognition over 12mths starting on Dec 1, 2008

Share Information



- Issued share capital at December 31: 5'862'492
 - nominal value CHF1
 - conditional capital: CHF1'993'746
- Free float: 98%
- Market capitalisation: CHF194.0 million

Pipeline Status Review

Allosteric Modulator Pipeline



| Partner | Screening & Hit-to-Lead | Lead Optimization | Preclinical | Phase I | Phase IIa | Phase IIb | Milestone |
|--|---|-------------------|-------------|---------|-----------|-----------|------------------|
| | ADX10059 MR (mGluR5 NAM) monotherapy in PPI responders (study 204): Gastroesophageal Reflux Disease (GERD) | | | | | | Data 2H09 |
| | ADX10059 MR (mGluR5 NAM) add-on in PPI partial responders (study 205): Gastroesophageal Reflux Disease (GERD) | | | | | | Data 2H09 |
| | ADX10059 MR (mGluR5 NAM) prophylaxis for frequent migraine (study 206): Migraine Prevention | | | | | | Data 1H10 |
| | ADX48621 (mGluR5 NAM): Parkinson's Disease Levodopa Induced Dyskinesia (PD-LID) | | | | | | PhIIa start 2H09 |
| Merck & Co., Inc. | ADX63365 (mGluR5 PAM): Schizophrenia* | | | | | | not disclosed |
| Ortho McNeil Janssen Pharmaceutica (J&J) | ADX71149 (mGluR2 PAM): Anxiety / Schizophrenia | | | | | | not disclosed |
| | ADX71943 (GABAB PAM): Pain / UI / GERD | | | | | | Ph I start 4Q09 |
| | ADX68692 (FSH NAM): Contraception / Osteoporosis | | | | | | Ph I start 1H10 |
| | Adenosine A3 Antagonist : Glaucoma | | | | | | |

*PAM = positive allosteric modulator
 NAM = negative allosteric modulator
 * & undisclosed indications*

Allosteric Modulators in Discovery



| Partner | Hit-to-Lead | Lead Optimization |
|-------------------|---|-------------------|
| Merck & Co., Inc. | mGluR4 PAM: Parkinson's Disease* | |
| | GLP1R PAM: Type II Diabetes | |
| | mGluR7 NAM: Depression / Post Traumatic Stress Disorder | |
| | mGluR2 NAM: Alzheimer's Disease / Depression | |
| | Type II Diabetes | |
| | Obesity | |
| | Migraine | |

*PAM = positive allosteric modulator
NAM = negative allosteric modulator
* & undisclosed indications*

2009 Academic Conference Schedule



- March 2009: Journées Francophones d'Hépatogastroentérologie et d'Oncologie Digestive (Paris)
 - Oral Presentation on 20 March 2009: Effects of ADX10059 MR on gastroesophageal reflux in healthy subjects (Study ADX10059-104)
- April 2009: American Academy of Neurology (Seattle)
 - Poster Presentation on 29 April 2009: Migraine Proof of Concept – Efficacy, safety and tolerability of ADX10059 in the acute treatment of migraine (Study ADX10059-201)
- June 2009: Digestive Disease Week (Chicago)
 - Poster Presentation on 1 June 2009: Tolerability and Effects of ADX10059 MR on gastroesophageal reflux in healthy subjects (Study ADX10059-104)
 - Oral Presentation on 2 June 2009: GERD Proof of Concept - Effects of ADX10059 on gastroesophageal reflux in GERD patients (Study ADX10059-203)

Q&A

www.addexpharma.com